These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34118292)

  • 1. The lipid paradox in neuroprogressive disorders: Causes and consequences.
    Morris G; Berk M; Walder K; O'Neil A; Maes M; Puri BK
    Neurosci Biobehav Rev; 2021 Sep; 128():35-57. PubMed ID: 34118292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered lipid metabolism in brain injury and disorders.
    Adibhatla RM; Hatcher JF
    Subcell Biochem; 2008; 49():241-68. PubMed ID: 18751914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Danlou Tablet Fought against Inflammatory Reaction in Atherosclerosis Rats with Intermingled Phlegm and Blood Stasis Syndrome and Its Mechanism Study].
    Chen J; Cai HW; Miao J; Xu XM; Mao W
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jun; 36(6):703-8. PubMed ID: 27491230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
    Kimak E; Zięba B; Duma D; Solski J
    Lipids Health Dis; 2018 Apr; 17(1):71. PubMed ID: 29618370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-atherosclerosis of oligomeric proanthocyanidins from Rhodiola rosea on rat model via hypolipemic, antioxidant, anti-inflammatory activities together with regulation of endothelial function.
    Zhou Q; Han X; Li R; Zhao W; Bai B; Yan C; Dong X
    Phytomedicine; 2018 Dec; 51():171-180. PubMed ID: 30466614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis.
    Pašková U
    Ceska Slov Farm; 2019; 68(6):219-228. PubMed ID: 31906689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
    Tselepis AD; John Chapman M
    Atheroscler Suppl; 2002 Dec; 3(4):57-68. PubMed ID: 12573364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipase A2 and small, dense low-density lipoprotein.
    Hurt-Camejo E; Camejo G; Sartipy P
    Curr Opin Lipidol; 2000 Oct; 11(5):465-71. PubMed ID: 11048889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative reactivity of the myeloperoxidase-derived oxidants HOCl and HOSCN with low-density lipoprotein (LDL): Implications for foam cell formation in atherosclerosis.
    Ismael FO; Proudfoot JM; Brown BE; van Reyk DM; Croft KD; Davies MJ; Hawkins CL
    Arch Biochem Biophys; 2015 May; 573():40-51. PubMed ID: 25795019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile.
    Hurt-Camejo E; Paredes S; Masana L; Camejo G; Sartipy P; Rosengren B; Pedreno J; Vallve JC; Benito P; Wiklund O
    Arthritis Rheum; 2001 Dec; 44(12):2761-7. PubMed ID: 11762936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G protein-coupled receptor 39 activation alleviates oxidized low-density lipoprotein-induced macrophage inflammatory response, lipid accumulation and apoptosis by inducing A20 expression.
    Chen L; Fang Z; Wang X; Sun X; Ge X; Cheng C; Hu H
    Bioengineered; 2021 Dec; 12(1):4070-4080. PubMed ID: 34288802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments.
    Morris G; Puri BK; Olive L; Carvalho A; Berk M; Walder K; Gustad LT; Maes M
    BMC Med; 2020 Oct; 18(1):305. PubMed ID: 33070778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies.
    Delporte C; Van Antwerpen P; Vanhamme L; Roumeguère T; Zouaoui Boudjeltia K
    Mediators Inflamm; 2013; 2013():971579. PubMed ID: 23983406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipin-1 contributes to modified low-density lipoprotein-elicited macrophage pro-inflammatory responses.
    Navratil AR; Vozenilek AE; Cardelli JA; Green JM; Thomas MJ; Sorci-Thomas MG; Orr AW; Woolard MD
    Atherosclerosis; 2015 Oct; 242(2):424-32. PubMed ID: 26288136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?
    Divchev D; Schieffer B
    Vasc Health Risk Manag; 2008; 4(3):597-604. PubMed ID: 18827909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native and myeloperoxidase-oxidized low-density lipoproteins act in synergy to induce release of resolvin-D1 from endothelial cells.
    Dufour D; Khalil A; Nuyens V; Rousseau A; Delporte C; Noyon C; Cortese M; Reyé F; Pireaux V; Nève J; Vanhamme L; Robaye B; Lelubre C; Desmet JM; Raes M; Boudjeltia KZ; Van Antwerpen P
    Atherosclerosis; 2018 May; 272():108-117. PubMed ID: 29597117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
    Hovland A; Retterstøl K; Mollnes TE; Halvorsen B; Aukrust P; Lappegård KT
    Scand Cardiovasc J; 2020 Oct; 54(5):274-279. PubMed ID: 32500743
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients.
    Rolla R; De Mauri A; Valsesia A; Vidali M; Chiarinotti D; Bellomo G
    J Nephrol; 2015 Dec; 28(6):749-55. PubMed ID: 25971848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.